Form 603 Notice of initial substantial shareholder Corporations Act Section 671B To: Clarity Pharmaceuticals Ltd (“CU6”, Ordinary Fully Paid) 1. Details of substantial shareholder Citigroup Global Markets Australia Pty Limited (ACN 003 114 832) and each of the related bodies corporate in the...
Becoming a substantial holder
Filed with ASX · · 5 pages · English
Release
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- Quarterly Activities/Appendix 4C Cash Flow Report
- Ph III CLARIFY trial target number of participants achieved
- Notice of Annual General Meeting/Proxy Form
- Ceasing to be a substantial holder
- SAR-bisPSMA Presentation - Drug & Device Conference
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals